Avisi Technologies Receives FDA IDE Approval to Initiate U.S. Clinical Trial for VisiPlate Glaucoma Treatment
Golden Seeds company, Avisi Technologies, has received Investigational Device Exemption (IDE) approval from the U.S. FDA for its glaucoma treatment device, VisiPlate. This regulatory milestone allows the company to launch the SAPPHIRE clinical trial, which will evaluate VisiPlate’s safety and efficacy in patients with open-angle glaucoma in the United States. Read more here.